Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA.

Cell Death Differ. 2013 Jul;20(7):858-68. doi: 10.1038/cdd.2013.28. Review.

2.

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A.

J Biol Chem. 2005 Dec 9;280(49):40599-608.

3.
4.

Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P.

J Neurochem. 2003 Jul;86(1):126-35.

5.

Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.

Azijli K, Yuvaraj S, Peppelenbosch MP, Würdinger T, Dekker H, Joore J, van Dijk E, Quax WJ, Peters GJ, de Jong S, Kruyt FA.

J Cell Sci. 2012 Oct 1;125(Pt 19):4651-61. doi: 10.1242/jcs.109587.

6.

Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.

Kavuri SM, Geserick P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D, Gollnick H, Neumann M, Wajant H, Leverkus M.

J Biol Chem. 2011 May 13;286(19):16631-46. doi: 10.1074/jbc.M110.148585.

7.

Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.

Qin JZ, Bacon PE, Chaturvedi V, Bonish B, Nickoloff BJ.

Exp Dermatol. 2002 Dec;11(6):573-83.

PMID:
12473065
8.

The dark side of TRAIL signaling.

Fulda S.

Cell Death Differ. 2013 Jul;20(7):845-6. doi: 10.1038/cdd.2013.36. No abstract available.

10.

MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.

Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FA.

Apoptosis. 2013 Jul;18(7):851-60. doi: 10.1007/s10495-013-0829-3.

PMID:
23456625
11.

Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling.

Sessler T, Healy S, Samali A, Szegezdi E.

Pharmacol Ther. 2013 Nov;140(2):186-99. doi: 10.1016/j.pharmthera.2013.06.009. Review.

PMID:
23845861
12.
13.

Targeting TRAIL towards the clinic.

Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, de Jong S, Nawrocki ST.

Curr Drug Targets. 2011 Dec;12(14):2079-90.

PMID:
21777191
14.

NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).

Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS.

Anticancer Res. 2000 Nov-Dec;20(6B):4243-55.

PMID:
11205254
15.

TRAIL signalling: decisions between life and death.

Falschlehner C, Emmerich CH, Gerlach B, Walczak H.

Int J Biochem Cell Biol. 2007;39(7-8):1462-75. Review.

PMID:
17403612
16.

Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.

Zhuang H, Jiang W, Zhang X, Qiu F, Gan Z, Cheng W, Zhang J, Guan S, Tang B, Huang Q, Wu X, Huang X, Jiang W, Hu Q, Lu M, Hua ZC.

J Mol Med (Berl). 2013 Feb;91(2):219-35. doi: 10.1007/s00109-012-0947-3.

PMID:
22948392
17.

Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade.

Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S, Saiki I, Sakurai H.

Mol Cancer Ther. 2006 Dec;5(12):2970-6.

18.

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

Srivastava RK.

Neoplasia. 2001 Nov-Dec;3(6):535-46. Review.

20.

Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.

Berg D, Stühmer T, Siegmund D, Müller N, Giner T, Dittrich-Breiholz O, Kracht M, Bargou R, Wajant H.

FEBS J. 2009 Dec;276(23):6912-27. doi: 10.1111/j.1742-4658.2009.07388.x.

Items per page

Supplemental Content

Support Center